Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity.

Autor:	López-Campos F; Deparment Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain., Conde-Moreno A; Deparment Radiation Oncology, Hospital Universitario y Politécnico La Fe, 46010 Valencia, Spain., Barrado Los Arcos M; Deparment Radiation Oncology, Hospital Universitario de Navarra, 31008 Pamplona, Spain., Gómez-Caamaño A; Deparment Radiation Oncology, Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain., García-Gómez R; Deparment Radiation Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain., Hervás Morón A; Deparment Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2021 Nov 12; Vol. 11 (11). Date of Electronic Publication: 2021 Nov 12.
DOI:	10.3390/jpm11111190
Abstrakt:	The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients-androgen deprivation therapy (ADT) alone-until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits-including significantly better overall survival (OS)-for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu